COMPASS Pathways (CMPS) to Release Quarterly Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is anticipated to post its Q4 2024 quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect COMPASS Pathways to post earnings of ($0.62) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Trading Up 0.3 %

Shares of NASDAQ CMPS traded up $0.01 during midday trading on Friday, hitting $3.93. The stock had a trading volume of 1,247,976 shares, compared to its average volume of 1,273,099. The firm has a market cap of $268.89 million, a P/E ratio of -1.79 and a beta of 2.28. COMPASS Pathways has a fifty-two week low of $3.16 and a fifty-two week high of $12.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company's 50-day simple moving average is $4.06 and its 200 day simple moving average is $5.28.

Remove Ads

Analyst Upgrades and Downgrades

CMPS has been the subject of several recent research reports. Canaccord Genuity Group dropped their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday. Maxim Group dropped their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 1st. HC Wainwright cut their price objective on shares of COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research report on Thursday. They set a "buy" rating and a $11.00 target price for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $21.83.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.